Fiasp® FlexTouch Prefilled Insulin Pens for Mealtime Control

What Fiasp® Is and How It Works

Fiasp® FlexTouch is a prefilled insulin aspart pen designed for rapid mealtime glucose control in adults and children 2 years and older with diabetes. It is an ultra‑fast formulation of insulin aspart that starts working within minutes to help limit post‑meal spikes. Many customers compare Fiasp Flextouch without insurance costs across borders when planning therapy.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We partner with vetted pharmacies to supply authentic brand medications at value‑focused pricing.

Fiasp uses niacinamide (vitamin B3) to speed early absorption after a subcutaneous injection. It can be given at the start of a meal or within 20 minutes after starting to eat. The FlexTouch pen delivers insulin in 1‑unit steps, up to a high single‑dose limit per injection, and is U‑100 (100 units/mL).

Dosage and Usage

• Use as a rapid mealtime insulin as part of a basal‑bolus plan or as directed by a clinician.
• Typical timing: at the beginning of a meal or within 20 minutes after the meal starts.
• Initial dose and ratios vary by patient, carbohydrate intake, and glucose targets.
• When switching from another rapid‑acting insulin, many patients start unit‑for‑unit with close monitoring.
• Prime a new FlexTouch pen per the device instructions before the first injection.
• Attach a new, sterile pen needle for each injection. Do not share pens or needles.
• Inject into approved areas: abdomen, thigh, buttock, or upper arm. Rotate sites to reduce lipodystrophy.
• Do not dilute or mix in the FlexTouch pen. Follow label guidance if mixing is ever prescribed.
• If a dose is missed, check blood glucose and follow the care plan. Do not double the next dose.
• Do not use the pen if the solution is cloudy, colored, or contains particles.
• Dispose of used needles in a sharps container. Keep the pen cap on when not in use.

• Unopened pens: refrigerate at 2–8°C (36–46°F). Do not freeze. Protect from light.
• After first use: keep at room temperature (below 30°C/86°F) or refrigerated. Discard after 28 days.
• Do not store with a needle attached. Avoid heat, direct sunlight, and car glove boxes.
• Travel: use insulated packs with cold packs, not ice touching the pen. Keep in carry‑on bags.
• On arrival, return unused pens to the refrigerator. Never use a pen that was frozen.

Benefits and Savings

Fiasp provides faster onset than traditional rapid‑acting insulins, helping reduce postprandial glucose excursions. The dosing window at mealtime or shortly after offers flexibility when eating patterns change. The FlexTouch device is simple to dial, requires low injection force, and delivers 1‑unit increments.

Many customers save 60–80% vs typical U.S. prices. Customers paying without insurance may find added value through Canadian pricing and pack‑size options.

See our promotions page for current offers, including any Fiasp Flextouch coupon if available.

Side Effects and Safety

• Hypoglycemia (shakiness, sweating, fast heartbeat, headache, hunger)
• Injection site reactions (redness, pain, itching), lipodystrophy, or cutaneous amyloidosis
• Weight gain or mild edema
• Allergic reactions such as rash or itching
• Upper respiratory or gastrointestinal symptoms reported in some patients

Serious risks include severe hypoglycemia, hypokalemia, and rare systemic allergy. Insulin with thiazolidinediones may cause or worsen heart failure. Adjust background insulin or sulfonylurea to reduce hypoglycemia risk. Do not share pens. Do not use during episodes of hypoglycemia or with known hypersensitivity to insulin aspart.

Onset Time

Fiasp begins to appear in circulation within minutes and starts lowering glucose shortly after injection. Many patients see peak effect around 1 hour, with a typical duration of 3–5 hours. Day‑to‑day results depend on meal size, timing, injection site, and activity. A1C improvements emerge as the dose is optimized over several weeks.

Compare With Alternatives

Several mealtime insulins are available. Humalog® (insulin lispro) is a rapid‑acting analog with a slightly later onset than Fiasp for many users. Apidra® (insulin glulisine) is another option with a rapid profile. NovoRapid® (insulin aspart) is the classic aspart formulation with an earlier dosing window than regular insulin but slower early absorption than Fiasp.

Some patients consider human regular insulin instead of ultra‑fast analogs. It has a slower onset and longer tail, so meal timing differs. For reference, see Humulin R 100u Ml 10ml for details on regular insulin vials.

Fiasp also comes in cartridge formats in some markets. Patients using cartridges may pair them with a reusable device. For device details, see the Novopen 4 Novo Nordisk product page. Always follow the labeled instructions for the exact product dispensed.

Combination Therapy

• Basal‑bolus: combine with long‑acting insulin; adjust basal or bolus to meet targets.
• With metformin: common in type 2 diabetes to reduce hepatic glucose output.
• With GLP‑1 receptor agonists: some regimens reduce prandial dose needs.
• With SGLT2 inhibitors or DPP‑4 inhibitors: monitor for hypoglycemia and adjust dosing.
• With sulfonylureas: consider lowering the sulfonylurea dose to limit hypoglycemia.
• Correction dosing: use a clinician‑directed sensitivity factor to correct high glucose.

Patient Suitability and Cost‑Saving Tips

Fiasp FlexTouch is suited for patients who need rapid mealtime insulin, including those with type 1 diabetes and many with type 2 diabetes requiring prandial coverage. It is not for intravenous use and is not the treatment for diabetic ketoacidosis. Use with caution when insulin needs change, such as with illness, stress, renal or hepatic impairment, or weight changes.

Those with a history of severe hypoglycemia or hypoglycemia unawareness should use close monitoring and a personalized plan. Pediatric use is established for ages 2 and older. During pregnancy or breastfeeding, care teams weigh goals and risks when selecting insulins and doses.

Cost‑saving tips include ordering multi‑month quantities when appropriate, planning refills ahead of travel, and storing pens correctly to use the full 28‑day in‑use period. Consider consolidating items in one shipment. You can upload the prescription once per product strength and keep reminders to reorder before running out. CanadianInsulin ships with prompt, express, cold‑chain handling.

Authoritative Sources

Novo Nordisk Fiasp product information

Health Canada Drug Product Database: Fiasp Product Monograph

FDA Prescribing Information for Fiasp (insulin aspart) injection

Order Fiasp® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is educational and does not replace professional medical advice. Always follow your prescriber’s guidance and the product’s approved labeling.